{"nct_id":"NCT06106308","title":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-04","start_date":"2024-02-27","start_date_type":"ACTUAL","primary_completion_date":"2026-11","primary_completion_date_type":"ESTIMATED","completion_date":"2027-01","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["CRDF"]}